Gut Bacteria Metabolite Fuels Psoriasis by Hijacking Skin Immune Cells
A gut-derived metabolite, indoxyl sulfate, drives psoriatic skin inflammation by reprogramming Th17 immune cells — and correlates with disease severity in humans.
Summary
Researchers have uncovered a molecular pathway linking gut bacteria to psoriasis severity. Using a mouse model of psoriasis, scientists found that indole-producing gut microbes generate a metabolite called indoxyl sulfate (I3S), which travels systemically and activates the aryl hydrocarbon receptor (AHR) in skin-resident Th17 immune cells. This activation alters chromatin accessibility — essentially rewiring gene expression — to amplify skin inflammation. Critically, serum I3S levels in human psoriasis patients tracked closely with disease severity, suggesting this gut-skin axis is clinically relevant. The findings position gut microbiota composition and I3S as potential therapeutic targets for a condition affecting millions worldwide.
Detailed Summary
Psoriasis is a chronic inflammatory skin condition driven by a complex interplay of genetics, immunity, and environment — but how these forces sustain long-term tissue damage has remained unclear. This study, published in Immunity, identifies a surprising culprit: metabolites produced by gut bacteria that remotely amplify skin inflammation.
Using the Card14E138A/+ mouse model, which spontaneously develops psoriasis-like skin inflammation, researchers found that disease onset reshaped not only local skin immunity but also the systemic metabolite landscape. They specifically identified indole-producing gut microbiota — not skin microbiota — as key drivers of psoriatic pathology, establishing an important gut-to-skin signaling axis.
Mechanistically, these intestinal microbes convert dietary tryptophan to indoles, which the host then metabolizes into indoxyl sulfate (I3S). I3S acts as a ligand for the aryl hydrocarbon receptor (AHR) expressed on skin Th17 cells. AHR activation modulates chromatin accessibility in these cells, effectively unlocking pro-inflammatory gene programs that sustain skin inflammation. This epigenetic mechanism explains how a circulating gut-derived signal can potentiate tissue-specific immune pathology.
In human cohorts, serum I3S levels correlated positively with psoriasis severity, lending translational weight to the mouse findings and suggesting I3S could serve as both a biomarker and therapeutic target.
Caveats include reliance on a single genetic mouse model, and the observational nature of the human correlation data — causality in human psoriasis remains to be established. Nevertheless, these findings open new avenues for targeting the gut microbiome, tryptophan metabolism, or the AHR pathway in psoriasis treatment.
Key Findings
- Indole-producing gut microbiota — not skin microbiota — drive psoriatic skin inflammation in a mouse model.
- Gut microbes generate indoxyl sulfate (I3S) via a tryptophan metabolic relay involving host enzymes.
- I3S activates AHR in skin Th17 cells, altering chromatin accessibility to amplify inflammation.
- Serum I3S levels correlate with psoriasis disease severity in human patient cohorts.
- Gut microbiota and the I3S–AHR axis are identified as potential therapeutic targets for psoriasis.
Methodology
Researchers used the Card14E138A/+ murine psoriasis model to study gut-skin immune interactions and systemic metabolite changes. Mechanistic studies examined AHR signaling and chromatin remodeling in skin Th17 cells. Human validation involved correlation analyses of serum I3S levels with clinical psoriasis severity scores in patient cohorts.
Study Limitations
Causal relationships were established primarily in a single genetic mouse model, which may not fully capture human psoriasis heterogeneity. The human data are correlational and cannot confirm that I3S directly drives disease severity in patients. Additional clinical and interventional studies are needed to validate the gut-skin axis as a therapeutic target.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: